Longbow Finance SA Purchases 13,287 Shares of Kenvue Inc. (NYSE:KVUE)

Longbow Finance SA raised its position in Kenvue Inc. (NYSE:KVUE) by 5.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 280,568 shares of the company’s stock after buying an additional 13,287 shares during the quarter. Longbow Finance SA’s holdings in Kenvue were worth $5,990,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in KVUE. Grove Bank & Trust boosted its stake in shares of Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares in the last quarter. Geneos Wealth Management Inc. acquired a new stake in shares of Kenvue in the 4th quarter valued at approximately $29,000. Fortitude Family Office LLC boosted its stake in shares of Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares in the last quarter. Ashton Thomas Securities LLC acquired a new stake in shares of Kenvue in the 3rd quarter valued at approximately $35,000. Finally, Versant Capital Management Inc boosted its stake in shares of Kenvue by 300.8% in the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after purchasing an additional 1,441 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Price Performance

Shares of Kenvue stock opened at $23.33 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The firm has a market capitalization of $44.72 billion, a PE ratio of 44.01, a price-to-earnings-growth ratio of 2.62 and a beta of 1.45. The business’s 50-day moving average price is $21.33 and its 200-day moving average price is $22.21. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Sell-side analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be given a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.52%. Kenvue’s payout ratio is 154.72%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. UBS Group cut their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and cut their target price for the stock from $25.00 to $24.00 in a research report on Thursday, December 12th. Barclays cut their target price on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Friday, January 17th. Canaccord Genuity Group cut their target price on shares of Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.